📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer. (2020)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.27681

PubMed Identifier: 32922659

Publication URI: http://europepmc.org/abstract/MED/32922659

Type: Journal Article/Review

Volume: 11

Parent Publication: Oncotarget

Issue: 34

ISSN: 1949-2553